Table 1.
Characteristics of the study group of patients with coexisting autoimmune pancreatitis and inflammatory bowel disease.
| Feature | Entire cohort [N = 96] |
|---|---|
| Gender [males] | 51 [53%] |
| Current age [years ± SD] | 40 ± 16 |
| Age at IBD diagnosis [years ± SD] | 32 ± 15 |
| Duration of IBD follow-up [years ± SD] | 7 ± 6 |
| Type of IBD, n [%] | |
| Crohn’s disease | 18 [19%] |
| Ulcerative colitis | 76 [79%] |
| IBDU | 2 [2%] |
| Montreal IBD classification, n [%] | |
| Age at CD diagnosis ≤ 16 years | 3/18 [17%] |
| Age at CD diagnosis 17–40 years | 7/18 [39%] |
| Age at CD diagnosis > 40 years | 8/18 [44%] |
| Ileal CD [L1] | 2/18 [11%] |
| Colonic CD [L2] | 7/18 [39%] |
| Ileocolonic CD [L3] | 7/18 [39%] |
| Upper gastrointestinal CD involvement [L4] | 2/18 [11%] |
| CD inflammatory phenotype [B1] | 16/18 [89%] |
| CD stricturing phenotype [B2] | 2/18 [11%] |
| CD penetrating phenotype [B3] | 0/18 [0%] |
| Perianal CD | 2/18 [11%] |
| UC E1 | 10/76 [13%] |
| UC E2 | 35/76 [46%] |
| UC E3 | 31/76 [41%] |
| EIM, n [%] | 21 [22%] |
| IBD-related interventions [past and present], n [%] | |
| Systemic steroids | 74 [77%] |
| Mesalamine | 75 [78%] |
| Immunomodulators | 48 [50%] |
| Biologicsa | 41 [43%] |
| IBD-related surgeryb | 16 [17%] |
| Number of IBD flares, median [IQR] | 2 [1–4] |
| Comorbidities, n [%] | 39 [41%] |
| Family history of IBD, n [%] | 19 [20%] |
| Active IBD status at the end of follow-up, n [%] | 14 [15%] |
| Age at AIP diagnosis [years ± SD] | 35 ± 16 |
| Duration of AIP follow-up [years ± SD] | 5 ± 4 |
| Predominant symptoms at the onset of AIP, n [%] | |
| Abdominal pain | 78 [81%] |
| Jaundice | 4 [4%] |
| Weight loss | 3 [3%] |
| Asymptomatic | 10 [11%] |
| AIP subtype, n [%] | |
| 1 | 19 [20%] |
| 2 | 69 [72%] |
| Undefined | 8 [8%] |
| AIP radiological subtype, n [%] | |
| Focal AIP presentation in imaging | 39 [41%] |
| Diffuse AIP presentation in imaging | 45 [47%] |
| Timing of diagnosis | |
| AIP diagnosis preceded IBD, n (%) | 22 [23%] |
| IBD diagnosis preceded AIP or concomitant diagnosis, n [%] | 74 [77%] |
| AIP-related treatments and course, n [%] | |
| Single steroid course with clinical response | 72/79 [91%] |
| Steroid refractory | 7/79 [9%] |
| Advanced therapyc | 18 [19%] |
| Number of AIP relapses, mean ± SD | 0.4 ± 0.9 |
| Active AIP status at the end of follow-up, n [%] | 5 [5%] |
aInfliximab, adalimumab, golimumab, certolizumab, vedolizumab, ustekinumab, etrolizumab.
bColectomy [n = 15], segmental intestinal resection [n = 1].
cImmunomodulator or biological therapy
Abbreviations: AIP—autoimmune pancreatitis, CD—Crohn’s disease, EIM—extraintestinal manifestations, IBD—inflammatory bowel disease, IBDU—inflammatory bowel disease unclassified, UC—ulcerative colitis.